Problem Endometriosis is an inflammatory disease characterized by the endometrial-like tissue growth outside of the uterine cavity. This ectopic growth leads to hormonal imbalances, systemic inflammation, and debilitating pain. This condition recurs in 40–50% of patients within 5 years of surgery, and it is mostly because of minimal residual disease (resulting from incomplete excision, invisible peritoneal lesions, or impaired immune clearance of remaining endometriotic cells as a result of surgical transient immunosuppression) [2]. Although it affects 10–15% of reproductive age women, there is currently no cure and current clinical management is limited to hormonal suppression, pain control and surgical excision [3]. Consequently, there is a critical need for non-invasive, targeted therapies that can modulate the immune response and minimize recurrence rates without compromising the patient’s reproductive health.